Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
|Poll|July 7, 2016
Subpleural Mass in 46-Year-Old Patient
Author(s)Cesar A. Moran, MD
A 46-year-old man presents with a cough and chest pain. Chest imaging shows a subpleural mass in his left upper lobe, and a biopsy is performed. What is your diagnosis?
Advertisement
Advertisement
Related to this article
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
3
MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma
4
SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit
5